Epstein–Barr viral infection is a global epidemiological problem

封面
  • 作者: Solomay T.V.1,2, Semenenko T.A.3,4
  • 隶属关系:
    1. Interregional Department No. 1 of the FMBA of Russia
    2. I.I. Mechnikov Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia
    3. National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of Russia
    4. I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia
  • 期: 卷 67, 编号 4 (2022)
  • 页面: 265-277
  • 栏目: REVIEWS
  • URL: https://journal-vniispk.ru/0507-4088/article/view/118217
  • DOI: https://doi.org/10.36233/0507-4088-122
  • ID: 118217

如何引用文章

全文:

详细

The number of studies devoted to Epstein-Barr viral infection (EBV infection) has been growing in recent years. However, they all relate to the clinical aspects of this problem. Epidemiology issues remain practically unexplored. A review of domestic and foreign publications has shown that at the present stage there is a high intensity of the epidemic process of EBV infection both in Russia and abroad. The main indicators of unfavorable epidemiological situation are the ubiquitous spread of the pathogen and the increase in the incidence of infectious mononucleosis in recent years. The deterioration of the epidemic situation of EBV infection is influenced by changes in the immunological reactivity of various population groups due to the spread of HIV, HBV, HCV, the causative agent of tuberculosis and SARS-CoV-2. The above makes it possible to classify the problem as a global one and determines the need for the rapid implementation of the system of epidemiological surveillance of EBV infection and optimization of the complex of preventive and anti-epidemic measures. Reducing the burden of EBV is possible only with the consolidated participation of specialists of various profiles.

作者简介

Tatyana Solomay

Interregional Department No. 1 of the FMBA of Russia; I.I. Mechnikov Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

编辑信件的主要联系方式.
Email: solomay@rambler.ru
ORCID iD: 0000-0002-7040-7653

Candidate of Medical Sciences, Senior Researcher at the Laboratory of Epidemiological Analysis and Monitoring of Infectious Diseases, I.I. Mechnikov Research Institute of Vaccines and Serums

俄罗斯联邦, 123182, Moscow; 105064, Moscow

Tatyana Semenenko

National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia

Email: solomay@rambler.ru
ORCID iD: 0000-0002-6686-9011
俄罗斯联邦, 123098, Moscow; 119048, Moscow

参考

  1. Solomay T.V., Semenenko T.A., Karazhas N.V., Rybalkina T.N., Kornienko M.N., Bosh’yan R.E., et al. Assessing risks of infection with herpes viruses during transfusion of donor blood and its components. Analiz riska zdorov’yu. 2020; (2): 135–42. https://doi.org/10.21668/health.risk/2020.2.15.eng (in Russian)
  2. Isakov V.A., ed. Herpesviral Infections in Human: Guidelines for Physicians [Gerpecvirusnye infektsii cheloveka: rukovodstvo dlya vrachey]. St. Petersburg: SpetsLit; 2013. (in Russian)
  3. Afonas’eva T.M. The meaning of Epstein-Barr virus infection in pregnancy pathology. Perinatal infection of the fetus. Zdorov’e i obrazovanie v XXI veke. 2017; 19(11): 13–7. https://doi.org/10.26787/nydha-2226-7425-2017-19-11-13-17 (in Russian)
  4. Agaeva M.I., Agaeva Z.A. Characteristic features of the course of herpesvirus infections during pregnancy. Klinicheskiy razbor v obshchey meditsine. 2022; (1): 49–55. https://doi.org/10.47407/kr2022.3.1.00118 (in Russian)
  5. Solomay T.V., Semenenko T.A., Tutel’yan A.V., Bobrova M.V. Epidemiological characteristics of Epstein-Barr virus infection. Zhurnal mikrobiologii, epidemiologii i immunologii. 2021; 98(6): 685–96. https://doi.org/10.36233/0372-9311-139 (in Russian)
  6. Greshnyakova V.A., Goryacheva L.G., Nikiforova A.O. Infectious mononucleosis: atypical manifestation. Detskie infektsii. 2022; 21(1): 62–5. https://doi.org/10.22627/2072-8107-2022-21-1-62-65 (in Russian)
  7. Popkova M.I., Utkin O.V. Features of the epidemic process of infectious mononucleosis in the Nizhny Novgorod region in the modern period. Zdorov’e naseleniya i sreda obitaniya. 2021; (4): 79–86. https://doi.org/10.35627/22195238/202133747986 (in Russian)
  8. Kharitonova L.A., Soboleva N.G. The role of the infectious factor in juvenile rheumatoid arthritis in children. Rossiyskiy vestnik perinatologii i pediatrii. 2018; 63(3): 59–63. https://doi.org/10.21508/1027-4065-2018-63-3-59-63 (in Russian)
  9. Barkhatova T.V., Senyagina N.E., Krasnov V.V. The spreading of the markers of herpesviral infections in case of chronic pathology of kidneys of children. Meditsinskiy al’manakh. 2011; (6): 196–9. (in Russian)
  10. Ruzhentsova T.A., Gorelov A.V. The value of acute respiratory viral infections in the development of chronic heart failure disease in children. Epidemiologiya i infektsionnye bolezni. 2012; (3): 42–6. (in Russian)
  11. Solomay T.V. Pathology of the gastrointestinal tract in infection caused by the Epstein-Barr virus. Infektsionnye bolezni: Novosti, mneniya, obuchenie. 2020; 9(3): 74–8. https://doi.org/10.33029/2305-3496-2020-9-3-74-78 (in Russian)
  12. Denisov L.A. Federal project “Strengthening public health” as the most important component of the national project “Demography”. Sanitarnyy vrach. 2021; (7): 40–55. https://doi.org/10.33920/med-08-2107-04 (in Russian)
  13. Cui X., Cao Z., Chen Q., Arjunaraja S., Snow A.L., Snapper C.M. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine. 2016; 34(34): 4050–5. https://doi.org/10.1016/j.vaccine.2016.06.021
  14. Correia S., Bridges R., Wegner F., Venturini C., Palser A., Middeldorp J.M., et al. Sequence variation of Epstein-Barr virus: viral types, geography, codon usage, and diseases. J. Virol. 2018; 92(22): e01132-18. https://doi.org/10.1128/JVI.01132-18
  15. Popkova M.I., Utkin O.V. Genetic diversity of the Epstein-Barr virus: a modern view of the problem. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2022; 99(1): 93–108. https://doi.org/10.36233/0372-9311-228 (in Russian)
  16. Sullivan K., Isabel S., Khodai-Booran N., Paton T.A., Abdulnoor M., Dipchand A.I., et al. Epstein-Barr virus latent gene EBNA-1 genetic diversity among transplant patients compared with patients with infectious mononucleosis. Clin. Transplant. 2019; 33(4): e13504. https://doi.org/10.1111/ctr.13504
  17. Borozan I., Zapatka M., Frappier L., Ferretti V. Analysis of Epstein-Barr virus genomes and expression profiles in gastric adenocarcinoma. J. Virol. 2018; 92(2): e01239-17. https://doi.org/10.1128/JVI.01239-17
  18. Luo B., Liu M., Chao Y., Wang Y., Jing Y., Sun Z. Characterization of Epstein-Barr virus gp350/220 gene variants in virus isolates from gastric carcinoma and nasopharyngeal carcinoma. Arch. Virol. 2012; 157(2): 207–16. https://doi.org/10.1007/s00705-011-1148-z
  19. Weiss E.R., Alter G., Ogembo J.G., Henderson J.L., Tabak B., Bakiş Y., et al. High Epstein-Barr virus load and genomic diversity are associated with generation of gp350-specific neutralizing antibodies following acute infectious mononucleosis. J. Virol. 2016; 91(1): e01562-16. https://doi.org/10.1128/JVI.01562-16
  20. Farrell P.J., White R.E. Do Epstein-Barr virus mutations and natural genome sequence variations contribute to disease? Biomolecules. 2021; 12(1): 17. https://doi.org/10.3390/biom12010017
  21. Blazquez A.C., Berenstein A.J., Torres C., Izquierdo A., Lezama C., Moscatelli G., et al. Comprehensive evolutionary analysis of complete Epstein-Barr virus genomes from Argentina and other geographies. Viruses. 2021; 13(6): 1172. https://doi.org/10.3390/v13061172
  22. Senyuta N.B., Smirnova K.V., Diduk S.V., Goncharova E.V., Shcherbak L.N., Gurtsevich V.E. Structural and functional characteristics of the LMP1 oncogene in patients with tumors associated and not associated with the Epstein-Barr virus. Molekulyarnaya genetika, mikrobiologiya i virusologiya. 2016; 34(2): 71–5. https://doi.org/10.18821/0208-0613-2016-34-2-71-75 (in Russian)
  23. Kerr J.R. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J. Clin. Pathol. 2019; 72(10): 651–8. https://doi.org/10.1136/jclinpath-2019-205822
  24. Yakushina S.A., Kisteneva L.B. Epstein-Barr virus (Herpesviridae: Gammaherpesvirinae: Lymphocryptovirus: Human gammaherpesvirus 4): replication strategies. Voprosy virusologii. 2020; 65(4): 191–202. https://doi.org/10.36233/0507-4088-2020-65-4-191-202 (in Russian)
  25. van Zyl D.G., Mautner J., Delecluse H.J. Progress in EBV vaccines. Front. Oncol. 2019; 9: 104. https://doi.org/10.3389/fonc.2019.00104
  26. Shi T., Huang L., Chen Z., Tian J. Characteristics of primary Epstein-Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China. J. Med. Virol. 2021; 93(8): 5048–57. https://doi.org/10.1002/jmv.26941
  27. Buschle A., Hammerschmidt W. Epigenetic lifestyle of Epstein-Barr virus. Semin. Immunopathol. 2020; 42(2): 131–42. https://doi.org/10.1007/s00281-020-00792-2
  28. Jangra S., Yuen K.S., Botelho M.G., Jin D.Y. Epstein-Barr virus and innate immunity: Friends or Foes? Microorganisms. 2019; 7(6): 183. https://doi.org/10.3390/microorganisms7060183
  29. Trisko A.A., Kolesnikova N.V., Avdeeva M.G., Chudilova G.A., Lomtatidze L.V. Peculiarities of cellular immunity in acute Epstein-Barr virus infection. Epidemiologiya i infektsionnye bolezni. 2015; 20(4): 13–6. (in Russian)
  30. van den Heuvel D., Jansen M.A., Bell A.I., Rickinson A.B., Jaddoe V.W., van Dongen J.J., et al. Transient reduction in IgA+ and IgG+ memory B cell numbers in young EBV-seropositive children: the Generation R Study. J. Leukoc. Biol. 2017; 101(4): 949–56. https://doi.org/10.1189/jlb.5VMAB0616-283R
  31. Nagovitsyna E.B. Modern approaches to diagnostics and treatment of Epstein-Barr virus infectious mononucleosis. Dal’nevostochnyy meditsinskiy zhurnal. 2016; (3): 45–50. (in Russian)
  32. Trebukhov A.V., Zhizheleva V.Yu., Mal’tseva M.V., Naydovskaya N.A. Features of the immune status of often and longterm sick children – residents of the Altai territory. Journal of Siberian Medical Sciences. 2019; (4): 30–40. https://doi.org/10.31549/2542-1174-2019-4-30-40 (in Russian)
  33. Solomay T.V., Semenenko T.A., Gotvyanskaya T.P., Konopleva M.V., Davtyan S.A., Suslov A.P., et al. The role of C-reactive protein, neopterin and melatonin in the diagnosis of Epstein-Barr virus infection. Immunologiya. 2021; 42(5): 502–10. https://doi.org/10.33029/0206-4952-2021-42-5-502-510 (in Russian)
  34. Mutsvunguma L.Z., Rodriguez E., Escalante G.M., Muniraju M., Williams J.C., Warden C., et al. Identification of multiple potent neutralizing and non- antibodies against Epstein-Barr virus protein with potential for clinical application and as reagents for mapping immunodominant epitopes. Virology. 2019; 536: 1–15. https://doi.org/10.1016/j.virol.2019.07.026
  35. Sharifipour S., Davoodi Rad K. Seroprevalence of Epstein-Barr virus among children and adults in Tehran, Iran. New Microbes New Infect. 2020; 34: 100641. https://doi.org/10.1016/j.nmni.2019.100641
  36. Mikhneva S.A., Martynov Yu.V., Kukhtevich E.V., Grishina Yu.Yu. Infectious mononucleosis: a spatiotemporal manifestation of the epidemic process. Zdorov’e naseleniya i sreda obitaniya. 2018; (10): 50–4. https://doi.org/10.35627/2219-5238/2018-307-10-50-54 (in Russian)
  37. Postanogova N.O., Sofronova L.V., Rysinskaya T.K. The prevalence of infectious mononucleosis among children of the Perm region. In: Proceedings of the Interregional Scientific and Practical Conference with International Participation «Topical Issues of Pediatrics» [Materialy mezhregional’noy nauchno-prakticheskoy konferentsii s mezhdunarodnym uchastiem «Aktual’nye voprosy pediatrii»]. Perm’: Knizhnyy format; 2017: 188–91. (in Russian)
  38. Bayanova T.A., Kudryavtseva D.P., Plotnikova Yu.K., Botvinkin A.D. The change in the incidence of some herpes virus infections in populations with a high prevalence of HIV infection. VICh-infektsiya i immunosupressii. 2019; 11(3): 75–84. https://doi.org/10.22328/2077-9828-2019-11-3-75-84. (in Russian)
  39. Koshy E., Mengting L., Kumar H., Jianbo W. Epidemiology, treatment and prevention of zoster: A comprehensive review. Indian J. Dermatol. Venereol. Leprol. 2018; 84(3): 251–62. https://doi.org/10.4103/ijdvl.IJDVL_1021_16
  40. James C., Harfouche M., Welton N.J., Turner K.M., Abu-Raddad L.J., Gottlieb S.L., et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull. World Health Organ. 2020; 98(5): 315–29. https://doi.org/10.2471/BLT.19.237149
  41. Cannon M.J., Schmid D.S., Hyde T.B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev. Med. Virol. 2010; 20(4): 202–13. https://doi.org/10.1002/rmv.655
  42. Xiong G., Zhang B., Huang M.Y., Zhou H., Chen L.Z., Feng Q.S., et al. Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. PLoS One. 2014; 9(6): e99857. https://doi.org/10.1371/journal.pone.0099857
  43. Sharifipour S., Davoodi Rad K. Seroprevalence of Epstein-Barr virus among children and adults in Tehran, Iran. New Microbes New Infect. 2020; 34: 100641. https://doi.org/10.1016/j.nmni.2019.100641
  44. Smatti M.K., Yassine H.M., AbuOdeh R., AlMarawani A., Taleb S.A., Althani A.A., et al. Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. PLoS One. 2017; 12(12): e0189033. https://doi.org/10.1371/journal.pone.0189033
  45. Zając P.W., Czarkowska-Pączek B., Wyczałkowska-Tomasik A. Prevalence and molecular epidemiology of CMV and EBV among nurses working in pediatrics, transplantology, and primary health care. J. Occup. Health. 2020; 62(1): e12112. https://doi.org/10.1002/1348-9585.12112
  46. Akhmedov Yu.A., Mamedov M.K., Dzhavadzade S.H., Soltanov A.A., Magamedli A.Yu. Seropositivity to Epstein-Barr virus among oncological patients and healthy persons living in Azerbaijan. Biomeditsina (Baku). 2018; (2): 6–9. (in Russian)
  47. Krasnov V.V., Pozdnyakova M.A., Kulova E.A., Obryadina A.P., Astrakhantseva I.V. The state of immunity to herpetic infections in children brought up in orphanages. Prakticheskaya meditsina. 2008; (6): 64. (in Russian)
  48. Kotlova V.B., Kokoreva S.P., Aralova E.V., Razuvaev O.A. Epstein-Barr viral infection in perinatology. Elektronnyy nauchno-obrazovatel’nyy vestnik Zdorov’e i obrazovanie v XXI veke. 2013; 15(8): 3–9. (in Russian)
  49. Zhebrun A.B., Kulyashova L.B., Ermolenko K.D., Zakrevskaya A.V. Spread of herpesvirus infections in children and adults in St. Petersburg according to seroepidemiologic study data. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2013; 90(6): 30–6. (in Russian)
  50. Solomay T.V., Semenenko T.A., Blokh A.I. Prevalence of Epstein-Barr virus antibodies in different age groups in Europe and Asia: a systematic review and meta-analysis. Zdravookhranenie Rossiyskoy Federatsii. 2021; 65(3): 276–86. https://doi.org/10.47470/0044-197X-2021-65-3-276-286 (in Russian)
  51. L’vov N.D., Dudukina E.A. Key issues of current and diagnosis of Epstein-Barr virus infection. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2013; (3): 24–32. (in Russian)
  52. Demina O.I., Chebotareva T.A., Mazankova L.N., Tetova V.B., Uchaeva O.N. Clinical manifestations of infectious mononucleosis in primary or reactivated herpes virus infection. Rossiyskiy vestnik perinatologii i pediatrii. 2020; 65(1): 37–44. https://doi.org/10.21508/1027-4065-2020-65-1-37-44 (in Russian)
  53. Rostgaard K., Balfour H.H. Jr., Jarrett R., Erikstrup C., Pedersen O., Ullum H., et al. Primary Epstein-Barr virus infection with and without infectious mononucleosis. PLoS One. 2019; 14(12): e0226436. https://doi.org/10.1371/journal.pone.0226436
  54. Kuri A., Jacobs B.M., Vickaryous N., Pakpoor J., Middeldorp J.M., Giovannoni G., et al. Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health. 2020; 20(1): 912. https://doi.org/10.1186/s12889-020-09049-x
  55. Trunova O.A., Romanenko T.A., Staren’kova O.V., Susidko V.V. Some aspects of the epidemic process of Esthtein-Barr viral infection. Universitetskaya klinika. 2017; (3-1): 204–9. (in Russian)
  56. Aglyamova T.A., Khaertynova I.M., Nugmanov R.T., Knyazeva O.Yu. Population aspects of the epidemiology of herpes viral infections in a large industrial city. Prakticheskaya meditsina. 2017; (4): 56–62. (in Russian)
  57. Burmagina I.A., Pozdeeva M.A., Agafonov V.M. Infectious mononucleosis the northern region. Sanitarnyy vrach. 2014; (11): 38–41. (in Russian)
  58. Puzyreva L.V., Safonov A.D. Infections caused by the Epstein-Barr virus in HIV-infected patients. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2016; 93(6): 108–16. (in Russian)
  59. Shostakovich-Koretskaya L.R., Litvin K.Yu., Kushnerova E.A., Belokon’ A.A., Lesnichaya A.A., Margitich I.N. The course of non-Hodgkin’s lymphomas associated with Epstein-Barr in patients with HIV with different variants of therapeutic tactics: clinical cases. Klinicheskaya infektologiya i parazitologiya. 2018; 7(4): 508–17. (in Russian)
  60. Rosseto J.H.F., Tenório J.R., Mamana A.C., Tozetto-Mendoza T.R., Andrade N.S., Braz-Silva P.H., et al. Epstein-Barr virus oral shedding and viremia and their association with oral hairy leukoplakia in HIV+ individuals. Oral Dis. 2021. https://doi.org/10.1111/odi.14001
  61. Farisyi M.A., Sufiawati I. Detection of Epstein-Barr virus DNA in saliva of HIV-1-infected individuals with oral hairy leukoplakia. Oral Dis. 2020; 26(Suppl. 1): 158–60. https://doi.org/10.1111/odi.13400
  62. Chaillon A., Nakazawa M., Rawlings S.A., Curtin G., Caballero G., Scott B., et al. Subclinical cytomegalovirus and Epstein-Barr virus shedding is associated with increasing HIV DNA molecular diversity in Peripheral blood during suppressive antiretroviral therapy. J. Virol. 2020; 94(19): e00927-20. https://doi.org/10.1128/JVI.00927-20
  63. Kuznetsov P.L., Parygin S.S. Clinical cases: mixed infection with hepatitis A, B, D against HIV infection with activation of the Epstein-Barr virus. In: «Topical Issues of Modern Medical Science and Healthcare»: Materials of the II International (72 All-Russian) Scientific and Practical Conference of Young Scientists and Students, the II All-Russian Forum of Medical and Pharmaceutical Universities «For Quality Education» [«Aktual’nye voprosy sovremennoy meditsinskoy nauki i zdravookhraneniya»: Materialy II Mezhdunarodnoy (72 Vserossiyskoy) nauchno-prakticheskoy konferentsii molodykh uchenykh i studentov, II Vserossiyskogo foruma meditsinskikh i farmatsevticheskikh vuzov «Za kachestvennoe obrazovanie»]. Ekaterinburg; 2017: 294–9. (in Russian)
  64. Suarez F., Lortholary O., Hermine O., Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven. Blood. 2006; 107(8): 3034–44. https://doi.org/10.1182/blood-2005-09-3679
  65. Solomay T.V., Semenenko T.A. Viral hepatitis B, C and infectious mononucleosis: epidemiological similarities and differences. Voprosy virusologii. 2020; 65(1): 27–34. https://doi.org/10.36233/0507-4088-2020-65-1-27-34 (in Russian)
  66. Solomay T.V., Semenenko T.A., Ivanova M.Yu. The role of Epstein-Barr viral infection and hepatitis B and C in liver pathology. Voprosy virusologii. 2019; 64(5): 215–20. https://doi.org/10.36233/0507-4088-2019-64-5-215-220 (in Russian)
  67. Yurlov K.I., Masalova O.V., Kisteneva L.B., Khlopova I.N., Samokhvalov E.I., Malinovskaya V.V., et al. Human herpesviruses increase the severity of hepatitis. Biology (Basel). 2021; 10(6): 483. https://doi.org/10.3390/biology10060483
  68. Bunchorntavakul C., Reddy K.R. Epstein-Barr virus and cytomegalovirus infections of the liver. Gastroenterol. Clin. North Am. 2020; 49(2): 331–46. https://doi.org/10.1016/j.gtc.2020.01.008
  69. Sterlikov S.A., Lisovskiy S.N., Kucheryavaya D.A., Gordina A.V., Dergachev A.V. Dynamics of tuberculosis incidence in the Russian Federation over the past 10 years. Tuberkulez i sotsial’no-znachimye zabolevaniya. 2019; (3): 86–7. (in Russian)
  70. Jackson C., Abubakar I. Ending tuberculosis in risk groups in Europe: challenges from travel and population movement. Euro Surveill. 2017; 22(12): 30489. https://doi.org/10.2807/1560-7917.ES.2017.22.12.30489
  71. Bogdanova E.V., Kiselevich O.K., Yusubova A.N., Panova O.V., Stakhanov V.A., Batyrov F.A. Accompanying infections in children with TB. Vestnik Rossiyskogo universiteta druzhby narodov. Seriya: Meditsina. 2008; (7): 59–65. (in Russian)
  72. Sinitsyn M.V., Bogorodskaya E.M., Rodina O.V., Kubrakova E.P., Romanova E.Yu., Bugun A.V. The damage of the central nervous system in the patients with tuberculosis in modern epidemiological conditions. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2018; 7(1): 111–20. https://doi.org/10.24411/2305-3496-2018-00015 (in Russian)
  73. Mordyk A.V., Sitnikova S.V., Puzyreva L.V., Nazarova O.I., Fursevich L.N. Manifestations of HIV infection associated with the results of treatment of tuberculosis in patients admitted to a specialized hospital. VICh-infektsiya i immunosupressii. 2015; 7(1): 69–75. (in Russian)
  74. Cantan B., Luyt C.E., Martin-Loeches I. Influenza infections and emergent viral infections in intensive care unit. Semin. Respir. Crit. Care Med. 2019; 40(4): 488–97. https://doi.org/10.1055/s-0039-1693497
  75. García-Martínez F.J., Moreno-Artero E., Jahnke S. SARS-CoV-2 and EBV coinfection. Med. Clin. (Engl. Ed.). 2020; 155(7): 319–20. https://doi.org/10.1016/j.medcle.2020.06.010
  76. Solomay T.V., Semenenko T.A., Filatov N.N., Vedunova S.L., Lavrov V.F., Smirnova D.I., et al. Reactivation of Epstein-Barr virus (Herpesviridae: Lymphocryptovirus, HHV-4) infection during Covid-19: epidemiological features. Voprosy virusologii. 2021; 66(2): 152–61. https://doi.org/10.36233/0507-4088-40 (in Russian)
  77. Paolucci S., Cassaniti I., Novazzi F., Fiorina L., Piralla A., Comolli G., et al. San Matteo Pavia COVID-19 Task Force. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int. J. Infect. Dis. 2021; 104: 315–9. https://doi.org/10.1016/j.ijid.2020.12.051
  78. Gold J.E., Okyay R.A., Licht W.E., Hurley D.J. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021; 10(6): 763. https://doi.org/10.3390/pathogens10060763
  79. Meng M., Zhang S., Dong X., Sun W., Deng Y., Li W., et al. COVID-19 associated EBV reactivation and effects of ganciclovir treatment. Immun. Inflamm. Dis. 2022; 10(4): e597. https://doi.org/10.1002/iid3.597
  80. Solomay T.V., Simonova E.G., Semenenko T.A. Scientific substantiation of the creation and prospects for the development of an epidemiological surveillance system for infection caused by the Epstein-Barr virus. Epidemiologiya i vaktsinoprofilaktika. 2022; 21(1): 21–31. https://doi.org/10.31631/2073-3046-2022-21-1-21-31 (in Russian)
  81. Prichard M.N., Keith K.A., Quenelle D.C., Kern E.R. Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Antimicrob. Agents Chemother. 2006; 50(4): 1336–41. https://doi.org/10.1128/AAC.50.4.1336-1341.2006
  82. Zacny V.L., Gershburg E., Davis M.G., Biron K.K., Pagano J.S. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J. Virol. 1999; 73(9): 7271–7. https://doi.org/10.1128/JVI.73.9.7271-7277.1999
  83. Ville S., Imbert-Marcille B.M., Coste-Burel M., Garandeau C., Meurette A., Cantarovitch D., et al. Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study. Transpl. Int. 2018; 31(5): 484–94. https://doi.org/10.1111/tri.13085
  84. Solomay T.V., Isaeva E.I., Vetrova E.N., Chernyshova A.I., Semenenko T.A., Panteleeva L.G. Evaluation of the effectiveness of chemical disinfection agents against the Epstein-Barr virus. Dezinfektsionnoe delo. 2021; (3): 40–8. https://doi.org/10.35411/2076-457X-2021-3-40-48 (in Russian)
  85. Cui X., Snapper C.M. Epstein Barr virus: Development of vaccines and immune cell therapy for EBV-associated diseases. Front. Immunol. 2021; 12: 734471. https://doi.org/10.3389/fimmu.2021.734471

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Problems of Virology, 2022

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».